SPY326.73-3.25 -0.98%
DIA264.51-2.08 -0.78%
IXIC10,967.96-217.64 -1.95%

Morgan Stanley Maintains Overweight on Abbott Laboratories, Lowers Price Target to $100

Morgan Stanley maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $108 to $100.

Benzinga · 06/25/2020 12:37
Morgan Stanley maintains Abbott Laboratories (NYSE: ABT) with a Overweight and lowers the price target from $108 to $100.